Desthiazolylmethyl Ritonavir | CAS# 256328-82-2 | Ritonavir Degradation Product

MedKoo Cat#: 574658 | Name: Desthiazolylmethyl Ritonavir

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Desthiazolylmethyl ritonavir is a base-catalyzed degradation product of ritonavir.

Chemical Structure

Desthiazolylmethyl Ritonavir

CAS#256328-82-2

Theoretical Analysis

MedKoo Cat#: 574658

Name: Desthiazolylmethyl Ritonavir

CAS#: 256328-82-2

Chemical Formula: C33H43N5O4S

Exact Mass: 605.3036

Molecular Weight: 605.80

Elemental Analysis: C, 65.43; H, 7.15; N, 11.56; O, 10.56; S, 5.29

Price and Availability

Size	Price	Availability
10mg	USD 300.00	2 Weeks
25mg	USD 650.00	2 Weeks
50mg	USD 1,050.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Ritonavir EP Impurity L, Ritonavir specified impurity L [EP], Ritonavir Impurity L

IUPAC/Chemical Name

(2S)-N-[(2S)-1-[(4S,5S)-4-benzyl-2-oxo-1,3-oxazolidin-5-yl]-3-phenylpropan-2-yl]-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanamide

InChi Key

YIFUFODEQQNFLV-AMEOFWRWSA-N

InChi Code

InChI=1S/C33H43N5O4S/c1-21(2)29(37-32(40)38(5)19-26-20-43-31(35-26)22(3)4)30(39)34-25(16-23-12-8-6-9-13-23)18-28-27(36-33(41)42-28)17-24-14-10-7-11-15-24/h6-15,20-22,25,27-29H,16-19H2,1-5H3,(H,34,39)(H,36,41)(H,37,40)/t25-,27-,28-,29-/m0/s1

SMILES Code

CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2C(NC(=O)O2)CC3=CC=CC=C3)CC4=CC=CC=C4

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Desthiazolylmethyl ritonavir is a degradation product of ritonavir.

In vitro activity:

Stimuli-sensitive nanomicelles along with hyaluronic acid targeting and ritonavir addition can effectively serve as a chemotherapeutic drug delivery agent for metastatic breast cancer and triple-negative breast cancer. Reference: Int J Mol Sci. 2021 Jan 27;22(3):1257. https://pubmed.ncbi.nlm.nih.gov/33513992/

In vivo activity:

Nirmatrelvir plus ritonavir reduced the overall risk for hospitalization or death after an outpatient diagnosis of COVID-19. Recipients of nirmatrelvir plus ritonavir had lower risk for hospitalization (adjusted risk ratio, 0.60 [CI, 0.44 to 0.81]) and death (adjusted risk ratio, 0.29 [CI, 0.12 to 0.71]). Reference: Ann Intern Med. 2023 Jan;176(1):77-84. https://pubmed.ncbi.nlm.nih.gov/36508742/

	Solvent	mg/mL	mM
Solubility
	DMF	10.0	16.51
	DMSO	2.0	3.30
	Ethanol	3.0	4.95

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 605.80 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Gote V, Sharma AD, Pal D. Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells. Int J Mol Sci. 2021 Jan 27;22(3):1257. doi: 10.3390/ijms22031257. PMID: 33513992; PMCID: PMC7865449. 2. Marima R, Hull R, Dlamini Z, Penny C. The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells. Biomed Pharmacother. 2020 Dec;132:110829. doi: 10.1016/j.biopha.2020.110829. Epub 2020 Oct 12. PMID: 33059259. 3. Loos NHC, Beijnen JH, Schinkel AH. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins. Biomed Pharmacother. 2023 Jun;162:114636. doi: 10.1016/j.biopha.2023.114636. Epub 2023 Apr 1. PMID: 37004323; PMCID: PMC10065864. 4. Dryden-Peterson S, Kim A, Kim AY, Caniglia EC, Lennes IT, Patel R, Gainer L, Dutton L, Donahue E, Gandhi RT, Baden LR, Woolley AE. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study. Ann Intern Med. 2023 Jan;176(1):77-84. doi: 10.7326/M22-2141. Epub 2022 Dec 13. PMID: 36508742; PMCID: PMC9753458.

In vitro protocol:

In vivo protocol:

1. Loos NHC, Beijnen JH, Schinkel AH. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins. Biomed Pharmacother. 2023 Jun;162:114636. doi: 10.1016/j.biopha.2023.114636. Epub 2023 Apr 1. PMID: 37004323; PMCID: PMC10065864. 2. Dryden-Peterson S, Kim A, Kim AY, Caniglia EC, Lennes IT, Patel R, Gainer L, Dutton L, Donahue E, Gandhi RT, Baden LR, Woolley AE. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study. Ann Intern Med. 2023 Jan;176(1):77-84. doi: 10.7326/M22-2141. Epub 2022 Dec 13. PMID: 36508742; PMCID: PMC9753458.

1: Rojas J, Lonca M, Imaz A, Estrada V, Asensi V, Miralles C, Domingo P, Montero M, Del Rio L, Fontdevila J, Perez I, Cruceta A, Gatell JM, Arnedo M, Martínez E. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir. HIV Med. 2016 May;17(5):340-9. doi: 10.1111/hiv.12314. Epub 2015 Sep 10. PubMed PMID: 27089862. 2: Yang W, Xiao Q, Wang D, Yao C, Yang J. Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results. Xenobiotica. 2016 Apr 6:1-11. [Epub ahead of print] PubMed PMID: 27052428. 3: Shiffman ML, Rustgi V, Bennett M, Forns X, Asselah T, Planas Vila R, Liu L, Pedrosa M, Moller J, Reau N. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 Apr 5. doi: 10.1038/ajg.2016.108. [Epub ahead of print] PubMed PMID: 27045929. 4: Pandie M, Wiesner L, McIlleron H, Hughes J, Siwendu S, Conradie F, Variava E, Maartens G. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother. 2016 Apr;71(4):1037-40. doi: 10.1093/jac/dkv447. Epub 2016 Jan 7. PubMed PMID: 26747099. 5: Menon RM, Klein CE, Podsadecki TJ, Chiu YL, Dutta S, Awni WM. Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers. Br J Clin Pharmacol. 2016 May;81(5):929-40. doi: 10.1111/bcp.12873. Epub 2016 Feb 24. PubMed PMID: 26710243. 6: Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. PubMed PMID: 26702926. 7: Lee FJ, Marriott D, Bloch M, Richardson R, Mackenzie N, Carr A. Post-prandial lipid effects of raltegravir versus darunavir/ritonavir in HIV-1-infected adults commencing combination ART. J Antimicrob Chemother. 2016 Apr;71(4):1127-9. doi: 10.1093/jac/dkv436. Epub 2015 Dec 18. PubMed PMID: 26682962. 8: Borges ÁH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES, Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P, Komati S, Kumar P, Lockman S, MacArthur RD, Maggiolo F, Matteelli A, Miro JM, Oka S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C, Lundgren JD. Non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based regimens for initial treatment of HIV infection: a systematic review and meta-analysis of randomised trials. Clin Infect Dis. 2016 Apr 18. pii: ciw236. [Epub ahead of print] PubMed PMID: 27090986. 9: Slama L, Landman R, Assoumou L, Benalycherif A, Samri A, Joly V, Pialoux G, Valin N, Cabié A, Duvivier C, Lambert-Niclot S, Marcelin AG, Peytavin G, Costagliola D, Girard PM; IMEA 040 DATA Study Group. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial). J Antimicrob Chemother. 2016 Apr 10. pii: dkw103. [Epub ahead of print] PubMed PMID: 27068399. 10: Łucejko M, Parfieniuk-Kowerda A, Flisiak R. Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection. Expert Opin Pharmacother. 2016 Apr 11. [Epub ahead of print] PubMed PMID: 27064432. 11: Gane EJ, Rouzier R, Hassanein T, Stedman CA, Mazur W, Kupcova V, Le Pogam S, Eng S, Voulgari A, Morcos PN, Brennan BJ, Scalori A, Thommes J. Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis. Hepatol Int. 2016 May;10(3):478-87. doi: 10.1007/s12072-015-9699-9. Epub 2016 Feb 17. PubMed PMID: 26886127. 12: LaFountaine JS, Jermain SV, Prasad LK, Brough C, Miller DA, Lubda D, McGinity JW, Williams RO 3rd. Enabling thermal processing of ritonavir-polyvinyl alcohol amorphous solid dispersions by KinetiSol® Dispersing. Eur J Pharm Biopharm. 2016 Apr;101:72-81. doi: 10.1016/j.ejpb.2016.01.018. Epub 2016 Feb 6. PubMed PMID: 26861929. 13: Calderón MM, Penzak SR, Pau AK, Kumar P, McManus M, Alfaro RM, Kovacs JA. Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects. Clin Infect Dis. 2016 Apr 15;62(8):1036-42. doi: 10.1093/cid/ciw028. Epub 2016 Jan 20. PubMed PMID: 26797214; PubMed Central PMCID: PMC4803107. 14: Khatri A, Dutta S, Wang H, Podsadecki T, Trinh R, Awni W, Menon R. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors. Clin Infect Dis. 2016 Apr 15;62(8):972-9. doi: 10.1093/cid/civ1213. Epub 2016 Jan 5. PubMed PMID: 26740513. 15: Dickinson L, Winston A, Boffito M, Khoo S, Back D, Siccardi M. Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. J Antimicrob Chemother. 2016 Apr;71(4):1041-5. doi: 10.1093/jac/dkv439. Epub 2015 Dec 27. PubMed PMID: 26712906. 16: Saab S, Gonzalez YS, Huber C, Wang A, Juday T. Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV. Liver Int. 2016 Apr;36(4):515-21. doi: 10.1111/liv.13033. Epub 2015 Dec 25. PubMed PMID: 26610059. 17: van Lunzen J, Pozniak A, Gatell JM, Antinori A, Klauck I, Serrano O, Baakili A, Osiyemi O, Sevinsky H, Girard PM. Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study. J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):538-43. doi: 10.1097/QAI.0000000000000904. PubMed PMID: 26605505; PubMed Central PMCID: PMC4804741. 18: Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F; MARAVIPEP Study Group. A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. J Antimicrob Chemother. 2016 Mar 18. pii: dkw048. [Epub ahead of print] PubMed PMID: 26994091. 19: Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F; RALPEP Study Group. A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. J Antimicrob Chemother. 2016 Mar 18. pii: dkw049. [Epub ahead of print] PubMed PMID: 26994089. 20: Kao JH, Tung SY, Lee Y, Thongsawat S, Tanwandee T, Sheen IS, Wu JJ, Li H, Brennan BJ, Zhou J, Le Pogam S, Najera I, Thommes JA, Hill G. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis. J Gastroenterol Hepatol. 2016 Mar 19. doi: 10.1111/jgh.13374. [Epub ahead of print] PubMed PMID: 26992248.